Aim: To provide information about psychiatric emergency situations in Japan, we examined psychiatrists' preference among parenteral medication since intramuscular (IM)-olanzapine became available and clinical characteristics in patients given IMolanzapine compared to those given other parenteral medication.
| INTRODUCTION
In psychiatric emergency settings, intramuscular (IM)/intravenous (IV) medications are indispensable measures against patients' extremely severe excitement and refusal to take an essential medicine. In a retrospective chart review, the availability of a rapidly disintegrating formulation of an atypical antipsychotic for emergent use reportedly did not reduce the use of IM antipsychotics or of seclusion or restraint in an acute inpatient psychiatric setting. 1 In the latest international survey among 21 countries consisting of 20 European countries and India, the distribution of parenteral medication use has been reported as follows:
haloperidol and lorazepam, 15 countries; second-generation antipsychotics, 13 countries; zuclopenthixol, 12 countries; low potency antipsychotics, 9 countries; intravenous medication, 3 countries. 2 In Japan, among first-generation antipsychotics, the use of IM-levomepromazine has gradually decreased due to concerns about side effects, whereas IM/IV-haloperidol has dominated practice in psychiatric emergency. In 2012, IM-olanzapine became available as the first atypical (second generation) antipsychotic drug except long-acting injectable antipsychotics in Japan. Accumulated evidence suggests that short-acting intramuscular formulations of second-generation antipsychotics are as effective as IM-haloperidol, and superior to IM-haloperidol in short-term tolerability. 3 Thus, the choice of parenteral medication in psychiatric emergency settings has been changing. In this naturalistic study proceeding over a 1-year period in 9 psychiatric emergency departments, we examined psychiatrists' preference among parenteral medication since IM-olanzapine became available to provide information about psychiatric emergency situations in Japan, and clinical characteristics in patients given IM-olanzapine compared to those given other parenteral medication.
| ME TH ODS

| Design
This was a naturalistic study proceeded over a 1-year period (June 1, 2014 to May 31, 2015) in 9 psychiatric emergency departments. All study protocols were approved by the institutional review board of Juntendo University School of Medicine and each institutional review board. The approved protocol did not require informed consent from patients, as the protocol was not different from ordinary practice, and as the data remained anonymous and were analyzed in aggregate.
| Clinical settings
In each area, psychiatric emergency patients requiring hospitalization are hospitalized under the responsibility of each of these hospitals.
Most of the patients from these hospitals were behavioral emergencies and about 60% of them were brought in by the police. edited by the Japanese Association for Emergency Psychiatry, but prescription was left to their discretion to a certain extent.
| Patients
Patients who required IM/IV medications at the time of admission or during emergency hospitalization due to extremely severe agitation and refusal to take an essential medicine were included. IM medication was chosen when there was little possibility of complication of somatic disease or abnormal physiological conditions. IV medication was chosen when uncooperative patients were required to receive CT, MRI, or lumbar puncture, or when uncooperative patients were required to receive fluid therapy due to dehydration, hypokalemia, or elevation of serum muscle enzymes such as creatine phosphokinase. Vital signs and the Drug-induced Extrapyramidal Symptom Scale (DIEPSS) 7 were also recorded at the time of an initial injection, 30 min, 60 min, 90 min, 1 day, 2 days, and 3 days after the initial injection. Electrocardiogram and any serious adverse events were recorded after injections.
| Statistical analysis
Data were collected on standardized forms and statistical analyses were performed using SPSS version 23-J software (IBM Japan, Tokyo, Japan 
| RESULTS
| The distribution of initial injections
During the study period, 4 252 patients admitted to the 9 psychiatric emergency departments. Among these, 197 patients received IM/IV medication (4.6%) were included in the study. Baseline characteristics of 197 patients were as follows: the mean age, 47.1 (SD 16.4); the proportion of men, 41.6%; Schizophrenia spectrum, 68.0%; substance dependence, 8.1%; drug-na€ ıve, 23.4%; the mean score of PANSS-EC, 25.3 (SD 6.7). As a reason for the injection, Thus, olanzapine and haloperidol were the first choice as an IM-and an IV-injection, respectively, among most psychiatrists in emergency situations. Details are shown in Table 1 . There were no significant differences in baseline characteristics among groups, except the item of "Uncooperativeness for CT/MRI" as a reason for the injection in which the rate of IV-benzodiazepine was significantly higher than others.
| The follow-up data up to 72 hours after the initial injection: additional injections, seclusion, or restraint
As shown in Table 2 , patients given IM-levomepromazine less frequently required an additional injection and an additional injection of another kind of drug followed by IM-olanzapine. In contrast, 86%
and 70% of patients whose initial injection was IV-haloperidol and IV-benzodiazepine, respectively, received additional injection. In particular, 59% of patients whose initial injection was IV-haloperidol required IV-benzodiazepine, and 80% of patients whose initial injection was IV-benzodiazepine required IV-haloperidol. Nevertheless, there was no significant difference in duration until patients became cooperative for oral administration among groups. Repeated-measures ANOVA revealed a significant main effect of time course 
| DISCUSSION
Before IM-olanzapine was available in Japan, parenteral haloperidol was considered a first-line treatment option by experts of the Japanese Association for Emergency Psychiatry. 8 The present study showed IV-haloperidol was still the most frequent, but it was followed by IM-olanzapine with a small difference (39.6% vs 33.5%).
Also, IM-levomepromazine was considered a first-line treatment option by 24% of the experts before IM-olanzapine was available, but the present study showed that it became less frequent (8.6%).
T Without physical management such as keeping venous lines, the necessity of restraint becomes low. As shown in Table 2 , the rate of restraint during the first 3 days after the initial injection was almost the same as that of an additional injection in the IV-haloperidol 
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